HOME

TheInfoList



Click Here for Items Related To - tissue-agnostic drug
OR:
tissue-agnostic drug on:   [Wikipedia]   [Google]   [Amazon]

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. Tissue-agnostic drugs that have been approved for medical use include
Pembrolizumab Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast canc ...
,
Larotrectinib Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. ...
,
Selpercatinib Selpercatinib, sold under the brand name Retevmo among others, is a medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET (gene), RET which is short for "rearranged during ...
,
Entrectinib Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin r ...
, and Pralsetinib.


History

Pembrolizumab was approved by the US
Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...
in May 2017. Larotrectinib was approved by the FDA in November, 2018. Selpercatinib (LOXO-292) received priority review in September 2018 and was approved for medical use in the United States in May 2020. Entrectinib was approved for medical use in the United States in August 2019, in Australia in May 2020, and in the European Union in July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Pralsetinib was approved for medical use in the United States in September 2020. Tissue-agnostic cancer drugs that are under development include Selitrectinib (Loxo-195) and anti-
ERBB3 Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ''ERBB3'' gene. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ ...
antibodies.


References

{{antineoplastic-drug-stub